| Nuclear phosphatidylinositol 4, 5-bisphosphate islets contribute to efficient RNA polymerase II-dependent transcription M Sobol, A Krausová, S Yildirim, I Kalasová, V Fáberová, V Vrkoslav, ... Journal of cell science 131 (8), jcs211094, 2018 | 67 | 2018 |
| Nuclear phosphoinositides—Versatile regulators of genome functions E Castano, S Yildirim, V Fáberová, A Krausová, L Uličná, D Paprčková, ... Cells 8 (7), 649, 2019 | 48 | 2019 |
| Tools for visualization of phosphoinositides in the cell nucleus I Kalasova, V Fáberová, A Kalendová, S Yildirim, L Uličná, T Venit, ... Histochemistry and cell biology 145 (4), 485-496, 2016 | 43 | 2016 |
| PIP2 epigenetically represses rRNA genes transcription interacting with PHF8 L Ulicna, A Kalendova, I Kalasova, T Vacik, P Hozák Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2018 | 36 | 2018 |
| Nuclear actin filaments recruit cofilin and actin-related protein 3, and their formation is connected with a mitotic block A Kalendová, I Kalasová, S Yamazaki, L Uličná, M Harata, P Hozák Histochemistry and Cell Biology 142 (2), 139-152, 2014 | 36 | 2014 |
| Paxillin-dependent regulation of IGF2 and H19 gene cluster expression P Marášek, R Dzijak, I Studenyak, J Fišerová, L Uličná, P Novák, P Hozák Journal of cell science 128 (16), 3106-3116, 2015 | 32 | 2015 |
| Phospholipids and inositol phosphates linked to the epigenome L Uličná, D Paprčková, V Fáberová, P Hozák Histochemistry and Cell Biology 150 (3), 245-253, 2018 | 16 | 2018 |
| Phosphoproteomic mapping reveals distinct signaling actions and activation of muscle protein synthesis by Isthmin-1 Meng Zhao, Niels Banhos Dannieskiold-Samsøe, Livia Ulicna, Quennie Nguyen ... Elife 11, e80014, 2022 | 12 | 2022 |
| The interaction of SWI/SNF with the ribosome regulates translation and confers sensitivity to translation pathway inhibitors in cancers with complex perturbations L Ulicna, SC Kimmey, CM Weber, GM Allard, A Wang, NQ Bui, ... Cancer research 82 (16), 2829-2837, 2022 | 12 | 2022 |
| Nuclear Phosphoinositides—Versatile Regulators of Genome Functions, Cells.(2019) E Castano, S Yildirim, V Fáberová, A Krausová, L Uličná, D Paprčková, ... | 6 | |
| ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models A Daemen, N Yuen, A Wang, A Pankov, L Ulicna, C Chen, FL Duong, ... Cancer Res 84, 6586-6586, 2024 | 4 | 2024 |
| Characterization of a phiBP endolysin encoded by the Paenibacillus polymyxa CCM 7400 phage J Ugorcakova, L Medzova, B Solteszova, G Bukovska FEMS microbiology letters 362 (13), fnv098, 2015 | 3 | 2015 |
| Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer MA Marx, AC Burns, N Arora, TP Bobinski, DM Briere, A Calinisan, ... Cancer Research 84 (7_Supplement), ND04-ND04, 2024 | 2 | 2024 |
| Multiple Aspects of PIP2 Involvement in C. elegans Gametogenesis L Ulicna, J Rohožková, P Hozak International journal of molecular sciences 19 (9), 2679, 2018 | 2 | 2018 |
| PRC2 inhibition enhances AR inhibitor response to delay treatment relapse in castration-sensitive prostate cancer by restricting adaptation of tumor cells in preclinical studies N Yuen, A Pankov, L Ulicna, J Long, X Chen, G Andreatta, A Wang, ... MOLECULAR CANCER THERAPEUTICS 24 (10), 2025 | | 2025 |
| Abstract C032: PRC2 inhibition enhances AR inhibitor response to delay treatment relapse in castration-sensitive prostate cancer by restricting adaptation of tumor cells in … N Yuen, A Pankov, L Ulicna, JE Long, X Chen, G Andreatta, AW Wang, ... Molecular Cancer Therapeutics 24 (10_Supplement), C032-C032, 2025 | | 2025 |
| Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lung and colorectal cancer models SW Ni, N Yuen, L Ulicna, DF Reyes, M Pawlak, FL Duong, JE Long, ... Molecular Cancer Therapeutics 24 (10_Supplement), A048-A048, 2025 | | 2025 |
| ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway … A Daemen, A Pankov, N Yuen, A Wang, L Ulicna, X Chen, FL Duong, ... Cancer Research 85 (8), 2025 | | 2025 |
| ORIC-613, a potential first-and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models KA Edgar, S McRee, G Andretta, C Chen, C Colas, W Fang, W Kong, ... Cancer Research 84 (6), 2024 | | 2024 |
| Phosphoproteomic mapping reveals distinct signaling actions and activation of muscle M Zhao, N Banhos Danneskiold-Samsøe, L Ulicna | | 2022 |
